IPQ Inside the global regulatory dialogue

The News in Depth

FDA, MHRA and WHO Guidances Shed Further Light on Data Integrity Concerns

Guidances issued between April and July 2016 by FDA, UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), and the World Health Organization (WHO) are providing a stronger foundation for the industry/regulator dialogue around the world on where the current gaps are in industry’s oversight of data integrity (DI) and how those gaps should be filled.

Industry/Regulator Dialogue on Knowledge Management is Intensifying in Wake of ICH’s Q12 Initiative

The focus has been intensifying at industry/regulator forums on how to evolve knowledge management programs, on the one hand, and the quality regulatory paradigm, on the other, to better support the goal of continuous improvement across the product lifecycle. 

IPQ Monthly Update – April / May 2016 in Review

In this Update, IPQ explores the complexities and challenges in both the downstream and upstream dimensions of the pharma supply chain. Downstream the IPQ focus continues on the ongoing FDA/industry efforts to implement a comprehensive track & trace system for RX drugs in the US: ● the first story, from the vantage point of FDA and pharma manufacturers ● and the second from that of the wholesalers and distributors. The issue then moves upstream to focus on: ● the divergent ways in which excipients are regulated by agencies around the world ● and how the biotech industry is cooperating to better control the raw materials needed to process and formulate its products.

Excipient Regulatory Approaches Globally Differ Widely in Registration, GMP, DMF, and Application Submission Expectations

An analysis of the way excipients are handled by regulators around the world reveals significant differences in the registration/licensing and GMP requirements as well as both the form and content of what needs to be submitted to support drug applications. 

Biopharmaceutical Industry Collaborating to Better Control Raw Material Quality Through Improved Supply Chain Communications

The biopharmaceutical industry is working collaboratively to expand its ability to control the quality of the wide variety of raw materials that are being used in production and formulation through improved communications across the increasingly complex supply chains involved.

Wholesalers and 3PLs Continue to Advocate for DSCSA Goals of Strong and Uniform Licensing and Pedigree Requirements Nationwide

Wholesale distributors and third party logistics (3PLs) providers are continuing to affirm their desire to take on more stringent licensing and pedigree requirements in exchange for clarity and uniformity of the expectations across the U.S.

FDA/Industry Track and Trace Pilot Planning Sheds Further Light on Complex Web of DSCSA Implementation Challenges

The complexity of the web of issues that need to be worked through to arrive at a fully interoperable track and trace system in the U.S. for prescription pharmaceuticals by 2023 as mandated by the Drug Supply Chain Security Act (DSCSA) was in full display at an FDA pilot planning workshop in early April.

IPQ Monthly Update – February / March 2016 in Review

IPQ continues its in-depth exploration of the changes FDA is making to its quality regulatory structure, processes and expectations – their impact and global significance. Focal points include: ● a progress report on OPQ’s first year ● the manufacturing innovation taking place in the more nourishing regulatory environment ● other key issues on the current OPQ agenda ● CDER’s new risk-based API review process, and ● reviewer concerns with biotech product excipients. Also covered on the international front are EDQM’s efforts to drive API regulatory harmonization.

EDQM’s International API Convergence Efforts Encompass Generics Regulator Forum IGDRP, Monographs and Inspections

The efforts by the European Directorate for the Quality of Medicines (EDQM) to further API quality regulatory harmonization include its participation in the International Generic Drug Regulators Program (IGDRP), which released in March a common form for submitting drug master files for active substances (ASMF/DMF), a common template for reviewing them, and a lexicon of common […]

FDA is Advising Biotech Product Applicants to More Clearly Justify Their Excipient Usage

FDA’s Office of Pharmaceutical Quality (OPQ) is asking biotech product sponsors to fully explain the process used to select excipients and to provide a risk assessment on potential interactions between the excipients and their proteins.
Pages: Prev 1 2 3 ...7 8 9 10 11 12 13 ...58 59 60 Next

Subscriber Login

Subscription Benefits

SUBSCRIBE TODAY and get 24/7 access to the IPQ family of publications:

● “In the News” — breaking stories on our website

● “News Alerts” — sent via email

● “Monthly Updates” — the key CMC and GMP developments in the US, Europe and internationally

● “Special Reports” — in-depth analysis of specific, emerging issues of regulator/industry concern

Documents and Archives — Live links to all the documents referenced in our stories and full access to IPQ’s valuable archive library


CLICK HERE for the IPQ Monthly Update – June 2019 in Review

IPQ takes its readers from:

● the headlines to the forces driving them

● regulations and policies to their underlying intent

● the pieces of the puzzle to their interconnection

● requirements to implementation pathways

● random data to critical trends

● the sidelines to helping shape the outcome

● compliance problems to proactive quality tools

● information to intelligence



©2019 IPQ Publications